Johan Karlsson Wallman
11 – 20 of 66
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Incidence of Clinically Diagnosed Psoriatic Arthritis in Sweden
- Contribution to journal › Article
-
Mark
Handling of missing component information for common composite score outcomes used in axial spondyloarthritis research when complete-case analysis is unbiased
- Contribution to journal › Article
-
Mark
Challenge of missing data in observational studies : investigating cross-sectional imputation methods for assessing disease activity in axial spondyloarthritis
- Contribution to journal › Article
-
Mark
Predictors of Secukinumab Treatment Response and Continuation in Axial Spondyloarthritis : Results From the EuroSpA Research Collaboration Network
- Contribution to journal › Article
- 2024
-
Mark
Sex Differences in the Effectiveness of First-Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis : Results From the European Spondyloarthritis Research Collaboration Network
- Contribution to journal › Article
-
Mark
Persistent pain and its predictors after starting anti-tumour necrosis factor therapy in psoriatic arthritis : what is the role of inflammation control?
- Contribution to journal › Article
-
Mark
Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor : results from 13 European registries
- Contribution to journal › Article
-
Mark
Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care
- Contribution to journal › Article
-
Mark
Treatment for Rheumatoid Arthritis Associated With Alterations in the Gastrointestinal Microbiota
- Contribution to journal › Article
-
Mark
Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis : a European routine-care observational study
- Contribution to journal › Article
